Cardiovascular Drugs Market Strategies and Share 2031
Cardiovascular diseases (CVD) is a class of diseases that involve conditions affecting the heart or blood vessels. Drugs are a primary medication used to control various parameters in the cardiovascular diseases. Some of the major diseases for which cardiovascular drugs are recommended by the doctor includes inflammatory heart disease, heart failure, angina and others.
MARKET DYNAMICS
The cardiovascular drugs market is anticipated to grow in the forecast, owing to increasing incidence of cardiovascular diseases across the globe, adoption of sedentary lifestyle and rising geriatric population. In addition, development of novel drugs by market players through strategic collaboration is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Cardiovascular Drugs Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of cardiovascular drugs market with detailed market segmentation by drug class, distribution channel and geography. The global cardiovascular drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading cardiovascular drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global cardiovascular drugs market is segmented on the basis of by drug class and distribution channel. Based on drug class, the market is segmented as, anti-hypertensive, anti-hyperlipidemics, anti-coagulants, anti-arrhythmic, anti-fibrinolytic, others. Based on distribution channel, the market is segmented in to hospital pharmacies, retail pharmacies, and online pharmacies.
REGIONAL FRAMEWORKThe report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global cardiovascular drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The cardiovascular drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting cardiovascular drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the cardiovascular drugs market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global cardiovascular drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The cardiovascular drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting cardiovascular drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the cardiovascular drugs market in these regions.
MARKET PLAYERSThe reports cover key developments in the cardiovascular drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from cardiovascular drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for cardiovascular drugs market in the global market. Below mentioned is the list of few companies engaged in the cardiovascular drugs market.
The report also includes the profiles of key cardiovascular drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Pfizer Inc.
- Bayer AG
- Novartis AG
- Merck KGaA
- Abbott
- Sun Pharmaceutical Industries Ltd.
- Gilead Sciences Inc.
- Takeda Pharmaceutical Company Ltd
- Eli Lily and Company
- Johnson & Johnson Services, Inc.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cardiovascular Drugs Market - By Drug Class
1.3.2 Cardiovascular Drugs Market - By Distribution Channel
1.3.3 Cardiovascular Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. CARDIOVASCULAR DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CARDIOVASCULAR DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CARDIOVASCULAR DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. CARDIOVASCULAR DRUGS - GLOBAL MARKET OVERVIEW
6.2. CARDIOVASCULAR DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CARDIOVASCULAR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ANTI-HYPERTENSIVE
7.3.1. Overview
7.3.2. Anti-Hypertensive Market Forecast and Analysis
7.4. ANTI-HYPERLIPIDEMICS
7.4.1. Overview
7.4.2. Anti-Hyperlipidemics Market Forecast and Analysis
7.5. ANTI-COAGULANTS
7.5.1. Overview
7.5.2. Anti-Coagulants Market Forecast and Analysis
7.6. ANTI-ARRHYTHMIC
7.6.1. Overview
7.6.2. Anti-Arrhythmic Market Forecast and Analysis
7.7. ANTI-FIBRINOLYTIC
7.7.1. Overview
7.7.2. Anti-Fibrinolytic Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. CARDIOVASCULAR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. CARDIOVASCULAR DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Cardiovascular Drugs Market Overview
9.1.2 North America Cardiovascular Drugs Market Forecasts and Analysis
9.1.3 North America Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.1.4 North America Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Cardiovascular Drugs Market
9.1.5.1.1 United States Cardiovascular Drugs Market by Drug Class
9.1.5.1.2 United States Cardiovascular Drugs Market by Distribution Channel
9.1.5.2 Canada Cardiovascular Drugs Market
9.1.5.2.1 Canada Cardiovascular Drugs Market by Drug Class
9.1.5.2.2 Canada Cardiovascular Drugs Market by Distribution Channel
9.1.5.3 Mexico Cardiovascular Drugs Market
9.1.5.3.1 Mexico Cardiovascular Drugs Market by Drug Class
9.1.5.3.2 Mexico Cardiovascular Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Cardiovascular Drugs Market Overview
9.2.2 Europe Cardiovascular Drugs Market Forecasts and Analysis
9.2.3 Europe Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Cardiovascular Drugs Market
9.2.5.1.1 Germany Cardiovascular Drugs Market by Drug Class
9.2.5.1.2 Germany Cardiovascular Drugs Market by Distribution Channel
9.2.5.2 France Cardiovascular Drugs Market
9.2.5.2.1 France Cardiovascular Drugs Market by Drug Class
9.2.5.2.2 France Cardiovascular Drugs Market by Distribution Channel
9.2.5.3 Italy Cardiovascular Drugs Market
9.2.5.3.1 Italy Cardiovascular Drugs Market by Drug Class
9.2.5.3.2 Italy Cardiovascular Drugs Market by Distribution Channel
9.2.5.4 Spain Cardiovascular Drugs Market
9.2.5.4.1 Spain Cardiovascular Drugs Market by Drug Class
9.2.5.4.2 Spain Cardiovascular Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Cardiovascular Drugs Market
9.2.5.5.1 United Kingdom Cardiovascular Drugs Market by Drug Class
9.2.5.5.2 United Kingdom Cardiovascular Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Cardiovascular Drugs Market Overview
9.3.2 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Cardiovascular Drugs Market
9.3.5.1.1 Australia Cardiovascular Drugs Market by Drug Class
9.3.5.1.2 Australia Cardiovascular Drugs Market by Distribution Channel
9.3.5.2 China Cardiovascular Drugs Market
9.3.5.2.1 China Cardiovascular Drugs Market by Drug Class
9.3.5.2.2 China Cardiovascular Drugs Market by Distribution Channel
9.3.5.3 India Cardiovascular Drugs Market
9.3.5.3.1 India Cardiovascular Drugs Market by Drug Class
9.3.5.3.2 India Cardiovascular Drugs Market by Distribution Channel
9.3.5.4 Japan Cardiovascular Drugs Market
9.3.5.4.1 Japan Cardiovascular Drugs Market by Drug Class
9.3.5.4.2 Japan Cardiovascular Drugs Market by Distribution Channel
9.3.5.5 South Korea Cardiovascular Drugs Market
9.3.5.5.1 South Korea Cardiovascular Drugs Market by Drug Class
9.3.5.5.2 South Korea Cardiovascular Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Cardiovascular Drugs Market Overview
9.4.2 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Cardiovascular Drugs Market
9.4.5.1.1 South Africa Cardiovascular Drugs Market by Drug Class
9.4.5.1.2 South Africa Cardiovascular Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Cardiovascular Drugs Market
9.4.5.2.1 Saudi Arabia Cardiovascular Drugs Market by Drug Class
9.4.5.2.2 Saudi Arabia Cardiovascular Drugs Market by Distribution Channel
9.4.5.3 U.A.E Cardiovascular Drugs Market
9.4.5.3.1 U.A.E Cardiovascular Drugs Market by Drug Class
9.4.5.3.2 U.A.E Cardiovascular Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Cardiovascular Drugs Market Overview
9.5.2 South and Central America Cardiovascular Drugs Market Forecasts and Analysis
9.5.3 South and Central America Cardiovascular Drugs Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Cardiovascular Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Cardiovascular Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Cardiovascular Drugs Market
9.5.5.1.1 Brazil Cardiovascular Drugs Market by Drug Class
9.5.5.1.2 Brazil Cardiovascular Drugs Market by Distribution Channel
9.5.5.2 Argentina Cardiovascular Drugs Market
9.5.5.2.1 Argentina Cardiovascular Drugs Market by Drug Class
9.5.5.2.2 Argentina Cardiovascular Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CARDIOVASCULAR DRUGS MARKET, KEY COMPANY PROFILES
11.1. PFIZER INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. MERCK KGAA
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ABBOTT
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GILEAD SCIENCES INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. TAKEDA PHARMACEUTICAL COMPANY LTD
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ELI LILY AND COMPANY
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. JOHNSON AND JOHNSON SERVICES, INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Pfizer Inc.
2. Bayer AG
3. Novartis AG
4. Merck KGaA
5. Abbott
6. Sun Pharmaceutical Industries Ltd.
7. Gilead Sciences Inc.
8. Takeda Pharmaceutical Company Ltd
9. Eli Lily and Company
10. Johnson & Johnson Services, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For